Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Deep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1

Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, Anna Rehammar, Erik Delsing Malmberg, Per-Ola Andersson, Mats L. Brune, Hege Kristin Gravdahl Garelius, Mats Hardling, Lars Palmqvist, Linda Fogelstrand

Blood (2023) 142 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2023-173497

Published: 2023

Journal Articles

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Caroline Weibull, Björn E Wahlin, MD PhD, Sandra Lockmer, Gunilla Enblad, Per-Ola Andersson, MD PhD, Eva Kimby, MD PhD, Karin E. Smedby, MD PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140228

Published: 2020

Journal Articles

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Karin Ekstroem Smedby, Sara Harrysson, MD, Sara Ekberg, Mats Jerkeman, MD PhD, Per-Ola Andersson, MD PhD, Gunilla Enblad, Sandra Eloranta

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138737

Published: 2020

Journal Articles

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Ljupco Veskovski, MD, Per-Ola Andersson, MD PhD, Ingemar Turesson, MD PhD, Daniel Malmodin, PhD, Anders Pedersen, PhD, Ulf-Henrik Mellqvist, MD PhD

Blood (2019) 134 (Supplement_1): 1771.

https://doi.org/10.1182/blood-2019-121961

Published: 2019

Journal Articles

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, MD Professor, Sverker Hasselblom, Björn E Wahlin, MD PhD, Per-Ola Andersson, MD PhD, Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 399.

https://doi.org/10.1182/blood-2019-122014

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Karin Ekstrom Smedby, MD PhD, Sara Harrysson, MD, Per-Ola Andersson, Gunilla Enblad, Sara Ekberg, Mats Jerkeman, Sandra Eloranta

Blood (2018) 132 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2018-99-116343

Published: 2018

Journal Articles

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Sara Harrysson, MD, Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Mats Jerkeman, Sverker Hasselblom, Björn E Wahlin, Per-Ola Andersson, Karin E Smedby

Blood (2018) 132 (Supplement 1): 2975.

https://doi.org/10.1182/blood-2018-99-110672

Published: 2018

Journal Articles

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Maria Winqvist, MSc, MD, Per-Ola Andersson, MD PhD, Anna Asklid, MD, Karin Karlsson, MD, Claes Karlsson, MD PhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD Assoc Prof, Mattias Mattsson, MD, Stefan Norin, MD PhD, Anna Bergendahl Sandstedt, MD, Lotta Hansson, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 5353.

https://doi.org/10.1182/blood.V130.Suppl_1.5353.5353

Published: 2017

Journal Articles

Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study

Krista Vaht, MD, Magnus Göransson, MD PhD, Kristina Carlson, MD PhD, Cecilia Isaksson, MD, Stig Lenhoff, Anna Sandstedt, MD, Bertil Uggla, MD PhD, Per T. Ljungman, MD PhD, Mats Brune, MD PhD, Per-Ola Andersson, MD PhD

Blood (2016) 128 (22): 3905.

https://doi.org/10.1182/blood.V128.22.3905.3905

Published: 2016

Journal Articles

Overexpression of Ribosomal Proteins Is Associated with Resistance to Immunochemotherapy in Diffuse Large B-Cell Lymphoma Patients

Martin Stenson, MD, Susanne Bram-Ednersson, MD, Herman Nilsson-Ehle, MD PhD, Mimmie Stern, MD, Gunilla Enblad, Sverker Hasselblom, MD PhD, Per-Ola Andersson, MD PhD

Blood (2016) 128 (22): 4121.

https://doi.org/10.1182/blood.V128.22.4121.4121

Published: 2016

Journal Articles

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chang Chai-Ni, Steen Lisby, Ira Gupta

Blood (2014) 124 (21): 4684.

https://doi.org/10.1182/blood.V124.21.4684.4684

Published: 2014

Journal Articles

Reactive Oxygen Species Produced By Myeloid Cells Block CD20-Antibody Dependent NK Cell-Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells

Olle Werlenius, MD, Johan Aurelius, PhD, Maria Simpanen, Rebecca E Riise, Ali A Akhiani, PhD, Anna Martner, PhD, Per-Ola Andersson, MD PhD, Kristoffer Hellstrand, MD, Fredrik B Thorén, PhD

Blood (2014) 124 (21): 3638.

https://doi.org/10.1182/blood.V124.21.3638.3638

Published: 2014

NARROW

Deep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Incidence and Outcome in Aplastic Anemia Diagnosed 2000-2011 - a Nationwide Swedish Registry Study

Overexpression of Ribosomal Proteins Is Associated with Resistance to Immunochemotherapy in Diffuse Large B-Cell Lymphoma Patients

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Reactive Oxygen Species Produced By Myeloid Cells Block CD20-Antibody Dependent NK Cell-Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only